[1] |
.首志雄. 原发性肝癌的多学科治疗进展[J]. 临床误诊误治,2013,26(5):103-106.
|
[2] |
.WANG Z,ZHANG G,WU J,et al.Adjuvant therapy for hepatocellular carcinoma:current situation and prospect[J]. Drug Discov Ther,2013,7(4):137-143.
|
[3] |
.DANIELE B,BENCIVENGA A,MEGNA A S,et al.Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma[J]. Gastroenterology,2004,127(5 Suppl 1):S108-S112.
|
[4] |
.中华医学会. 临床诊疗指南(肿瘤分册)[M]. 北京:人民卫生出版社,2005:325-326.
|
[5] |
.周建光,杨梅,曹海涛,等. 肿瘤标志物对原发性肝癌的诊断意义[J]. 医学综述,2013,19(12):3891-3893.
|
[6] |
.SHIRAHA H,YAMAMOTO K,NAMBA M.Human hepatocyte carcinogenesis[J]. Int J Oncol,2013,42(4):1133-1138.
|
[7] |
.赵培雷,郭平. 凝血酶敏感蛋白-1在肿瘤中的研究进展[J]. 国际肿瘤学杂志,2011,38(11):823-826.
|
[8] |
.RENNEMEIER C,HAMMERSCHMIDT S,NIEMANN S,et al.Thrombospondin-l promotes cellular adherence of gram-positive pathogens via recognition of peptidoglycan[J]. FASEB J,2007,21(12):3118-3132.
|
[9] |
.胡海涛,沈世强. 国内肝细胞癌患者血清中血管内皮生长因子表达的Meta分析[J]. 肝胆外科杂志,2011,19(5):345-350.
|
[10] |
.YAMAUCHI M,IMAJOH-OHMI S,SHIBUYA M.Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle[J]. Cancer Sci,2007,98(9):1491-1497.
|
[11] |
.KAZEROUNIAN S,DUQUETTE M,REYES M A,et al.Priming of the vascular endothelial growth factor signaling pathway by thromhospondin-1,CD36,and spleen tyrosine kinase[J]. Blood,2011,117(17):4658-4666.
|
[12] |
.ALLEGRINI C,COULETTE F A,DARNOWSKI J W,et al.Thrombospondin-1 plus irinotecan:a novel antiangiogenic-chemotherapeutic combination that inhihits the growth of advanced human colon tumor xenografts in mice[J]. Cancer Chemother Pharmacol,2004,53(3):261-266.
|
[13] |
.文卫,杨连粤,黄耿文,等. TSP-1和VEGF在肝细胞癌新生血管生成中的作用[J]. 中华肝胆外科杂志,2005,11(1):17-19.
|